More than 70% of early phase synthetic drug molecules are poorly bioavailable due to low aqueous solubility.

Amorphous solid dispersion technology is the most broadly applicable technology platform with precedence in performance, stability, and manufacturability for molecules with a wide range of physicochemical properties (brick dust, lipohilic, pH dependent solubility, etc).

This technology, along with our practical experience and scientific expertise, offers you the ability to scale a formulation from early phase screening (mgs) to large commercial production (tons) and is ideal for incorporation into traditional solid dosage forms, especially tablets.

• Technology selection: identification of problem statement and connection of target product profile with technology capabilities
• Discovery support and lead candidate optimization/selection
• Mechanistic biorelevant dissolution and performance testing, paired with phase appropriate biomodelling to support design hypotheses and formulation selection
• Physical and chemical stability predictive studies
• Model-based SDD and drug product formulation and process design workflows to reduce risk and API utilization

Utilizing material sparing workflows and model-based process design and scale up, we have everything necessary for development, scale-up, and GMP supply of your amorphous dispersion and solid oral dosage form.

Scalable spray driers

• Milligram quantity formulation screening to pilot scale (300 kg/h gas flow)
• Fully solvent capable (flammables and chlorinated solvents)
• Commercial PSD-4 spray dryer (1,250 kg/h gas flow), online in 2026

Full range of small-scale oral solid dose process equipment such as

• Bin blending
• Granulation: Gerteis roller compaction
• Milling: hammer and cone milling
• Solid dosage form compression and encapsulation
• Tablet coating: functional and cosmetic

Formal analytical method development and phase appropriate verification/validation